Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2014

Published: Feb, 2014 | Pages: 114 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2014', provides an overview of the Mitsubishi Tanabe Pharma Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mitsubishi Tanabe Pharma Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Mitsubishi Tanabe Pharma Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Mitsubishi Tanabe Pharma Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Mitsubishi Tanabe Pharma Corporation's pipeline products

Reasons to buy

- Evaluate Mitsubishi Tanabe Pharma Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Mitsubishi Tanabe Pharma Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Mitsubishi Tanabe Pharma Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Mitsubishi Tanabe Pharma Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mitsubishi Tanabe Pharma Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Mitsubishi Tanabe Pharma Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Mitsubishi Tanabe Pharma Corporation Snapshot 8
Mitsubishi Tanabe Pharma Corporation Overview 8
Key Information 8
Key Facts 8
Mitsubishi Tanabe Pharma Corporation - Research and Development Overview 9
Key Therapeutic Areas 9
Mitsubishi Tanabe Pharma Corporation - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Partnered Products/Combination Treatment Modalities 17
Pipeline Products - Out-Licensed Products 19
Out-Licensed Products/Combination Treatment Modalities 20
Mitsubishi Tanabe Pharma Corporation - Pipeline Products Glance 21
Mitsubishi Tanabe Pharma Corporation - Late Stage Pipeline Products 21
Pre-Registration Products/Combination Treatment Modalities 21
Filing rejected/Withdrawn Products/Combination Treatment Modalities 22
Phase III Products/Combination Treatment Modalities 23
Mitsubishi Tanabe Pharma Corporation - Clinical Stage Pipeline Products 24
Phase II Products/Combination Treatment Modalities 24
Phase I Products/Combination Treatment Modalities 26
Mitsubishi Tanabe Pharma Corporation - Early Stage Pipeline Products 27
Preclinical Products/Combination Treatment Modalities 27
Mitsubishi Tanabe Pharma Corporation - Drug Profiles 28
(canagliflozin + metformin) IR 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
telaprevir 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
teneligliptin 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
(canagliflozin + metformin) XR 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
bepotastine besylate 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
colestilan chloride 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
edaravone 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
encenicline 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
fingolimod hydrochloride 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
infliximab 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
cariprazine 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CYR-101 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
M-5200 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
masilukast 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
MT-1303 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
MT-3995 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
nalfurafine hydrochloride 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
osemozotan 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MT-4580 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
GB-1057 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MP-124 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MP-157 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
TT-138 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
WF-516 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Monoclonal Antibodies for Undisclosed Indication 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecule to Inhibit Aurora A Kinase for Solid Tumor 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecule to Inhibit DPP-IV for Hyperglycemia 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecule to Inhibit GSK-3 Beta for Alzheimers Disease 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecule To Inhibit Sodium and hERG Channel For Ischemic Stroke 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecule to Inhibit Sodium Channels for Ischemic Stroke 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
TA-3404 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Y-320 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Mitsubishi Tanabe Pharma Corporation - Pipeline Analysis 75
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Target 75
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Route of Administration 78
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Molecule Type 79
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action 80
Mitsubishi Tanabe Pharma Corporation - Recent Pipeline Updates 82
Mitsubishi Tanabe Pharma Corporation - Dormant Projects 101
Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products 103
Discontinued Pipeline Product Profiles 103
masilukast 103
sofigatran 104
activated charcoal 104
AV-412 104
caldaret 104
coleneuramide 104
colestilan chloride 105
DEZ-001 105
edaravone 105
immune globulin intravenous 105
marimastat 105
masilukast 105
MP-136 106
MP-435 106
MT-7716 106
netoglitazone 106
TA-5493 106
TA-5538 106
TA-6666 107
Y-700 107
Mitsubishi Tanabe Pharma Corporation - Company Statement 108
Mitsubishi Tanabe Pharma Corporation - Locations And Subsidiaries 109
Head Office 109
Other Locations & Subsidiaries 109
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 114
Disclaimer 114

List of Tables
Mitsubishi Tanabe Pharma Corporation, Key Information 8
Mitsubishi Tanabe Pharma Corporation, Key Facts 8
Mitsubishi Tanabe Pharma Corporation - Pipeline by Indication, 2014 11
Mitsubishi Tanabe Pharma Corporation - Pipeline by Stage of Development, 2014 13
Mitsubishi Tanabe Pharma Corporation - Monotherapy Products in Pipeline, 2014 14
Mitsubishi Tanabe Pharma Corporation - Combination Treatment Modalities in Pipeline, 2014 15
Mitsubishi Tanabe Pharma Corporation - Partnered Products in Pipeline, 2014 16
Mitsubishi Tanabe Pharma Corporation - Partnered Products/ Combination Treatment Modalities, 2014 17
Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products in Pipeline, 2014 19
Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2014 20
Mitsubishi Tanabe Pharma Corporation - Pre-Registration, 2014 21
Mitsubishi Tanabe Pharma Corporation - Filing rejected/Withdrawn, 2014 22
Mitsubishi Tanabe Pharma Corporation - Phase III, 2014 23
Mitsubishi Tanabe Pharma Corporation - Phase II, 2014 24
Mitsubishi Tanabe Pharma Corporation - Phase I, 2014 26
Mitsubishi Tanabe Pharma Corporation - Preclinical, 2014 27
Mitsubishi Tanabe Pharma Corporation - Pipeline by Target, 2014 76
Mitsubishi Tanabe Pharma Corporation - Pipeline by Route of Administration, 2014 78
Mitsubishi Tanabe Pharma Corporation - Pipeline by Molecule Type, 2014 79
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action, 2014 80
Mitsubishi Tanabe Pharma Corporation - Recent Pipeline Updates, 2014 82
Mitsubishi Tanabe Pharma Corporation - Dormant Developmental Projects,2014 101
Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products, 2014 103
Mitsubishi Tanabe Pharma Corporation, Other Locations 109
Mitsubishi Tanabe Pharma Corporation, Subsidiaries 110